Sbir phase 1 diagnostics to enable malaria and neglected tropical diseases
Ended Definitive Contract Awarded Last action
- Contract number
- 75N93018C00021
- Awardee
-
Hemex Health Inc. UEI LSJ7WFKBJWW4
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $225,000
Award facts
- Opportunity
-
- PHS201801 Solicitation number
- Contract value 100% obligated
- $225,000.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 16 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Portland, OR 97239, USA
- Research
- SBIR Program Phase I Action
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $225,000 |
About this award
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) under the Department of Health and Human Services. The contract, valued at $225,000.00, was awarded to Hemex Health Inc., a for-profit medical diagnostics company that develops affordable point-of-care tests for diseases like sickle cell and malaria. The contract is focused on developing diagnostic solutions to enable the detection and monitoring of malaria and neglected tropical diseases. Specific projects include improving the Gazelle Rapid Hemoglobin-Oxygen Dissociation Assay (RHODA) for sickle cell disease screening and treatment, using machine learning to enhance hemoglobin variant identification in newborns, and creating a rapid diagnostic test for Plasmodium vivax malaria.
Quick answers
Who was awarded contract 75N93018C00021?
75N93018C00021 was awarded to Hemex Health Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 31, 2018.
How much is contract 75N93018C00021 worth?
The government has obligated $225,000 on 75N93018C00021.
Was contract 75N93018C00021 competed?
The extent of competition for 75N93018C00021 was full and open competition after exclusion of sources. The government received 16 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award